AVITA Medical, Inc. (RCEL)
15.88
-0.11
(-0.69%)
USD |
NASDAQ |
Nov 20, 10:00
AVITA Medical Cash from Operations (Quarterly) : -0.6192M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.6192M |
| June 30, 2026 | -3.630M |
| March 31, 2026 | -10.07M |
| December 31, 2025 | -5.474M |
| September 30, 2025 | -5.538M |
| June 30, 2025 | -10.44M |
| March 31, 2025 | -10.31M |
| December 31, 2024 | -7.062M |
| September 30, 2024 | -7.613M |
| June 30, 2024 | -12.82M |
| March 31, 2024 | -20.86M |
| December 31, 2023 | -10.68M |
| Date | Value |
|---|---|
| September 30, 2023 | -8.594M |
| June 30, 2023 | -8.896M |
| March 31, 2023 | -9.073M |
| December 31, 2022 | -2.972M |
| September 30, 2022 | -2.337M |
| June 30, 2022 | -3.408M |
| March 31, 2022 | -9.37M |
| June 30, 2021 | -3.610M |
| March 31, 2021 | -9.598M |
| December 31, 2020 | -5.824M |
| September 30, 2020 | -7.713M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | -4.47M |
| Halozyme Therapeutics, Inc. | 258.27M |
| Agenus, Inc. | -20.10M |
| Amgen, Inc. | 4.241B |
| Fate Therapeutics, Inc. | -27.89M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 1.854M |
| Cash from Financing (Quarterly) | 0.1378M |
| Free Cash Flow | -19.42M |
| Free Cash Flow Per Share (Quarterly) | -0.0236 |
| Free Cash Flow to Equity (Quarterly) | 0.6174M |
| Free Cash Flow to Firm (Quarterly) | 0.765M |
| Free Cash Flow Yield | -3.95% |